Tag Archives: MTC

PR Newswire

United Imaging Introduces Next-Generation PET/CT Systems and Integrated Molecular Technology Platform at SNMMI

Leave a comment

With uMI Panorama™, United Imaging Continues to Push the Envelope on Whole-Body System Performance

HOUSTON, June 26, 2023 /PRNewswire/ — United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and a Leadership Circle sponsor at this year’s SNMMI, is making news on several fronts at SNMMI’s annual meeting in Chicago this week.

“There has been a debate in the marketplace for a while about the relative importance of resolution, axial field of view (FOV), and time of flight (TOF),” said Jeffrey Bundy, Ph.D, CEO of United Imaging Healthcare Solutions about the company’s product launch. “With the new wide-bore uMI Panorama and its 2.9 mm NEMA resolution, 35 cm axial FOV and 194 ps timing resolution, we will gladly have a conversation on any single specification or the collective benefit of all of them, because with this particular product, the need to compromise is gone.”

The uMI Panorama was teased recently in the media as one of United Imaging’s four new products in four different imaging modalities so far this year. Cheri Gottke, Vice President of the Molecular Imaging portfolio for the U.S., added that the uMI Panorama is currently installed at Huntsman Cancer Center in Salt Lake City, Utah and that “we chose SNMMI as the official stage to debut it.”   

United Imaging is showcasing a cutting-edge Molecular Imaging technology platform along with the uMI Panorama, called uExcel. The platform integrates hardware and software innovations to optimize performance, imaging capabilities and system functionalities. Its ultra-digital platform (UDP) detector boasts a high-performance ASIC chip, and its AI-empowered workflow streamlines operations and enhances examination efficiency. Exceptional image quality can be achieved with a lower dose, and the quality assurance module maintains peak performance of the system.

The uMI Panorama is a family of products that also includes a 510k pending system with a 148 cm axial FOV, the uMI Panorama GS. Built on the uExcel platform, this ultra-long axial FOV system allows for fast and high-resolution whole-body PET/CT imaging in a single bed position. The uMI Panorama GS is also being unveiled at SNMMI.  

United Imaging continues to see steady acceleration in demand for its popular digital PET/CT the uMI® 550, in both mobile and fixed configurations. “This is one of our most important molecular imaging innovations,” continued Gottke. “The entire digital portfolio from the uMI 550 to the uMI Panorama offers exceptional PET and CT image quality that improves quantitative accuracy and small lesion detectability. Our portfolio includes All-In Configurations™ and Software Upgrades for Life™ so that all our scanners truly stand the test of time from both a technological and a clinical perspective.”

The entire uMI portfolio is also “Born with AI” from the ground up, rather than being retrofitted with it later. This allows a seamless integration of artificial intelligence (AI) across all products, which optimizes daily workflow, improves the patient experience, and creates stunning diagnostic images. United Imaging’s artificial intelligence (uAI®) streamlines routine clinical workflows by auto iso-centering patients and defining the scan range. Its systems also allow faster scanning with less dose, while improving PET and CT imaging quality and providing image consistency in all clinical settings, from academic to freestanding imaging centers. 

SNMMI announced in its Value Initiative Newsletter that United Imaging is joining the Leadership Circle and taking an Industry co-chair position. 

United Imaging this week is also hosting two Satellite Symposiums (available for registration on the SNMMI meeting website) and a by-invitation-only customer event: 

uEXPLORER Symposium on June 25: “Exploring the Unmatched Capabilities of Total Body Imaging: Reflections on 5 Years of Clinical Adoption”; presenters include Dr. Ramsey Badawi, Vice Chair for Research, Department of Radiology, University of California, Davis and Dr. Harshad Kulkarni, Chief Medical Advisor, BAMF Health.

uMI Panorama Symposium on June 26: “Advancing Precision Medicine with Unprecedented PET/CT Technology for Clinical Molecular Imaging” on Monday, June 26, from 11:30 am – 12:30 pm. Presenters include Dr. Jeffrey Yap, Director, Center for Quantitative Imaging at Huntsman Cancer Institute.

United Imaging Educational Evening “UIH Night” (Invitation Only), Sunday June 25th. Presenters include Dr. Richard Carson, Professor of Biomedical Engineering and Radiology, Yale University and Dr. Simon Cherry, Professor of Biomedical Engineering and Radiology, UC Davis

United Imaging is located at booth #4032.

ABOUT UNITED IMAGING
At United Imaging, we develop and manufacture advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change.

To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC.

Source: United Imaging Healthcare Co., Ltd.

PR Newswire

Jim Lim joins Zühlke Group as Head of Health & Medtech in Singapore

Leave a comment

SINGAPORE, April 21, 2023 /PRNewswire/ — Zühlke Group is pleased to announce the appointment of Jim Lim as Head of Market Unit (Health & Medtech) at Zühlke Asia. Based in Singapore, Jim will lead the organisation’s regional efforts to serve the healthcare industry and continue to expand Zühlke’s healthcare expertise and offerings to the ecosystems of healthcare providers, pharmaceutical and medtech companies in Asia.

Jim Lim, Head of Health & Medtech - Zühlke Asia
Jim Lim, Head of Health & Medtech – Zühlke Asia

With over 24 years of ICT industry experience, Jim brings his wealth of experience providing strategic, business and technological advice to global clients. Having held various senior leadership positions across MNCs, Jim has served clients across multiple industry verticals such as healthcare, pharmaceutical, medtech, telecommunications, financial services, education and manufacturing. Jim was also the founding CEO of Good Doctor Technology, a joint venture between Ping An Good Doctor, Grab and Softbank.

Outside his corporate career, Jim is the co-founder of a socio-techno network focused on bringing together the expertise, experiences and connections of senior executives globally to contribute back to society. He is appointed Senior Fellow by the Singapore University of Social Sciences and Executive Education Fellow by the National University of Singapore. He also serves as an industry mentor for Young NTUC and Vice President for Cloud Security Alliance Singapore Chapter.

Driving the future of health innovation through impactful work

Jonas Trindler, CEO Asia, Member of Group Executive Board & Partner of Zühlke Group, commented, “We’re actively contributing to significant breakthroughs in the health markets, with the pandemic accelerating digitalisation across health ecosystems. Together with our clients, we are solving critical challenges in this space to improve healthcare with quality and access. We are confident that Jim’s extensive experience and strategic leadership will enable us to drive further growth and meaningful innovation in the health and medtech space.”

“Asia is paving the way for next-generation digital healthcare and medtech ecosystems. I look forward to leading Zühlke’s health market at such an exciting time and contributing to impactful innovation to transform and provide sustainable healthcare to the everyday lives of people,” commenting on his new role, Jim said.

Zühlke – Empowering Ideas.

Zühlke is a global innovation service provider. We envisage ideas and create new business models for our clients by developing services and products based on new technologies – from the initial vision through development to deployment, production, and operation. We specialise in strategy and business innovation, digital solutions, and application services – in addition to device and systems engineering. Our outstanding solutions provide unique business value and a reliable foundation for sustained success.

Zühlke was founded in Switzerland in 1968 and is owned by its partners. Our 1,900 employees are based in Austria, Bulgaria, Germany, Hong Kong, Portugal, Serbia, Singapore, Switzerland, the United Kingdom and Vietnam, serving clients from a wide range of industries. In addition, our venture capital arm Zühlke Ventures provides start-up financing in the high-tech sector.

Contact: Lorraine Lai, lorraine.lai@zuhlke.com, +6569217800

PR Newswire

uLab® Launches the Orthodontics Industry’s First Suite of Practice-Branded Packaging Options

Leave a comment

MEMPHIS, Tenn., April 19, 2023 /PRNewswire/ — uLab Systems™, the creator of the uSmile™ clear aligner platform and the new uAssist™ concierge service, announces it now offers orthodontists a suite of branding options that give them the ability to create a variety of custom-designed packaging products that will enhance the patient experience and can help grow new business. Since 2021, uLab customers have benefited from the option to package a patient’s aligner in a box designed with the orthodontist’s name and/or logo. Now, the aligner pouch and aligner case can also perform as marketing platforms and will come as a custom-branded package with the box. In addition, orthodontists can now order branded typodonts and patient brochures for their in-office consultations. The new suite of custom options will be available in May.  

An example suite of custom logo items for patient aligner cases manufactured by uLab Systems for Wu Orthodontics.
An example suite of custom logo items for patient aligner cases manufactured by uLab Systems for Wu Orthodontics.

“The ability to brand the aligner package, pouch, and aligner case with our practice logo allowed us to provide the patient with a unique, personalized experience,” says Dr. Kevin Oliviera from Coastal Orthodontics, a member of the pilot group that trialed the customized items. “When a patient is presented with a custom-branded package, it reinforces the value of receiving a high-quality aligner that was designed by someone they know and trust. The patient’s confidence in us and their peace of mind are invaluable,” he adds. Dr. Oliviera also notes that the branded items are giving his/her practice much more visibility in the community. “They are terrific marketing tools that distinguish us from other practices.”

Orthodontists develop long-term relationships over the course of their career with the communities where they practice, even treating several generations of families.  “At uLab, we believe it’s more important that our customers promote their brand rather than the manufacturer’s,” says Amir Abolfathi, chief executive officer and co-founder of uLab.  “It is the orthodontist’s expertise and their patient care that help create beautiful smiles. uLab provides them with the innovative software tools and proven materials they need to develop an effective treatment, but it is ultimately up to them to create the smiles. Their brand and expertise are what patients should associate with quality results.”

uLab is dedicated to innovating for the orthodontic specialty, providing practitioners with easy access to innovative, state-of-the-art tools that enable the flexibility to control the patient treatment plan, unencumbered by pricing structure confines and restrictive protocols. The company has delivered on that commitment since its inception with the release of its in-office aligner design and printing software, uSmile aligners, the uAssist concierge service, and now its custom packaging capabilities. uLab has future plans for “all-digital” platform options, enhanced AI-guided planning tools, and features to enable direct print outputs.

uSmile aligners are manufactured in Memphis, Tennessee, and can be delivered in as few as three business days*. The uLab platform allows orthodontists ultimate control over their aligner treatments. More than 800,000 aligner treatment cases have been planned to date.

* Shipment times may vary depending on location and delivery time selection.

About uLab Systems
uLab Systems is led by an experienced team of healthcare innovators helping to transform options for orthodontic practices to provide the best outcomes for their patients. uLab’s mission is to advance the orthodontic industry with aligner products and digital treatment planning software that let orthodontists take back control of their treatment plans. To learn more visit www.ulabsystems.com. Contact: David Thrower, Chief Commercial Officer, pr@ulabsystems.com

© 2023 uLab Systems, Inc. All Rights Reserved. uLab Systems, uSmile, uAssist, uView, Smart Outcomes, and Smart Office are trademarks and uLab and uDesign are registered trademarks of uLab Systems, Inc. MAR-0001304 Rev 1
Now available! Orthodontists that want to promote their brand for patient aligner cases will now receive custom logo aligner pouches and an aligner case packaged with the custom logo box.
Now available! Orthodontists that want to promote their brand for patient aligner cases will now receive custom logo aligner pouches and an aligner case packaged with the custom logo box.

Photo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options-2.jpg
Photo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options.jpg
Logo – https://techent.tv/wp-content/uploads/2023/04/ulab-launches-the-orthodontics-industrys-first-suite-of-practice-branded-packaging-options-1.jpg

Source: uLab Systems, Inc.

PR Newswire

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES RESIDENCY AT JLABS @ SHANGHAI

Leave a comment

SINGAPORE, April 10, 2023 /PRNewswire/ — Respiree announced today that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’)[1] from February 21, 2023 , in order to expand its footprint with the goal of deepening its relationships and networks within the pharma and life science sector.

Respiree’s team at JLABS will focus on utilizing the iRIS One decentralized clinical trials platform with the aim to optimize drug trials and discover newer lung and cardiac digital biomarkers. Respiree’s team also aims to extend development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.

“We are very proud and excited to be joining the JLABS ecosystem. We hope to enhance the iRIS One clinical trials platform.  Through our expanded connectivity we also hope to further develop our digital therapeutics pipeline with the ultimate aim of enabling patients to access better treatments faster,” said Respiree’s CEO and Founder Dr Gurpreet Singh.

Respiree received the 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration (FDA) on 8 March 2023.

[1] Johnson & Johnson Innovation

About Respiree

Respiree is a digital therapeutics company providing personalized healthcare services for cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. Respiree is deployed internationally. Respiree’s iRIS One clinical trials platform is CE marked, approved for use in Australia by the Therapeutics Goods Administration and just received 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration.

PR Newswire

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Leave a comment

Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board

LONDON, March 24, 2023 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Jonathan Gear, Chief Executive Officer, Clarivate said: “I’m very pleased to announce the appointment of Gordon who has been a trusted and valued member of our Executive Leadership Team since he came to Clarivate from CPA Global as part of our acquisition in 2020. In this newly created role, he will be responsible for accelerating the growth of our IP segment empowering customers to establish, protect and manage their IP.

Based on my experience working with him over the last eight months and the work we’ve done this year to align the organization, I’m confident that he will be instrumental to how we capitalize on product and service innovation to deliver organic growth. This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course.”

Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer. During the last three years with Clarivate, Samson has made significant contributions, helping transform the Company’s APAC region and bringing together the Company’s entire product portfolio to offer customers a full range of enriched data, insights, analytics and workflow solutions. He has a long and successful track record of driving organizational transformation and growth in the IP industry and beyond, having held senior executive roles with both operating and P&L accountability for more than 20 years.

Andy Snyder, Chairman of the Board, Clarivate commented: “We look forward to Dr. Saha joining our Board. He will bring a great deal of experience in the pharmaceutical and biotech industries and his guidance will provide valuable insights and perspective, especially as we continue to execute on our growth strategy in the Life Sciences & Healthcare segment.”

Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel life-changing medicines. He is notable for leading the development and demonstrating human effectiveness of two innovative cancer drugs, an ERK kinase inhibitor (Ulixertinib) and an oncolytic immunotherapy (C. novyi-NT). He is currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), a global pharma company. Prior to Centessa, Dr. Saha was a Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol Myers Squibb. Other past roles include Venture Partner at Atlas Venture, a VC firm in Cambridge MA, Chief Executive Officer at Delinia, Chief Medical Officer of Synlogic, a management consultant at McKinsey & Company, and head of the New Indications Discovery Unit at Novartis. He is an associate member and Global Clinical Scholar at Harvard Medical School, holds an MD and PhD in medicine and cancer genetics from The Johns Hopkins School of Medicine, an MSc in biophysics from the University of Oxford and a BSc in biochemistry from Caltech.

About Clarivate

Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

Investor Relations Contact
Mark Donohue, Head of Investor Relations, investor.relations@clarivate.com, +1 (215) 243 2202

Media Contact
Amy Bourke-Waite, Senior Director, Corporate Communications, newsroom@clarivate.com

PR Newswire

Martech platform Ortto celebrates record growth on the anniversary of its rebrand

Leave a comment

The unified customer data, analytics, and marketing automation platform Ortto, formerly Autopilot, continues to see double-digit monthly growth a year on from its rebrand. The martech company now has more than 3,000 customers globally and was recognized in 49 categories in G2’s biannual report.

SYDNEY, March 8, 2023 /PRNewswire/ — Ortto, which started as Autopilot Journeys in 2015, rebranded in early 2022 following the launch of a revolutionary new platform that allows marketers to effortlessly connect previously siloed data sources to get a complete view of their customers. Marketers can analyze and operationalize this data without the need for specialized support, enabling them to deliver personalized customer journeys at scale, increasing the impact of their campaigns with powerful event-based triggers and AI-content optimization. In the year since the rebrand, Ortto’s users have built some 5,000 journeys and sent more than 210 million emails to their customers, contributing to the  company’s sustained 16% month-on-month growth.

Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.
Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.

  • The powerful platform received the ‘High Performer’ badge in 11 categories in the G2 Winter 2023 reports, including marketing automation and marketing platform, across multiple regions (APAC, ANZ, Europe, UK, etc.)
  • Ortto was also awarded the ‘Best estimated ROI’ badge and the ‘Easiest to use’ badge in the customer journey mapping categories, as well as the ‘Users Love Us’ badge.
  • The platform was also ranked number one for data personalization by SoftwareReviews.

Customer, Mica Shtewi, Tech Manager at Pattern, comments:

“When you’re moving into a world we’re moving into, you have so many data sources that you’re trying to bring together and various communications to get clients moving through the sales process. We needed something flexible that works and had a robust integration with Salesforce, and with Ortto we can target people the way we want to target them.”

Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.
Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.

Michael Sharkey, CEO and co-founder of Ortto, comments:

“Everyone recognizes the importance of data in building better, more personalized customer experiences, but the problem is, for many businesses, this data is located across a number of different tools and isn’t easily accessible to marketers. That’s why we rebuilt our platform to make it easy to bring all of that data together in one place and remove the barriers to entry, so marketers have ready access to the data they need without having to lodge a ticket or learn SQL. The response to the new platform has been incredible – not only from our Autopilot customers, who are realizing new value through Ortto, but also from new customers who have come on board in the past year.”

About Ortto

Ortto, the world’s first complete marketing automation, AI and analytics platform, empowers marketers to act with confidence and increase their impact on revenue. By combining three powerful tools into one intuitive platform, teams finally benefit from their customer data, messaging, and analytics working together.

Sophisticated yet easy to use, more than 3,000 customers trust Ortto to understand their impact, discover their next marketing opportunity, and continuously iterate to deliver great customer experiences at scale. Learn more at: www.ortto.com 

Launched in 2015, Ortto’s team is located in Australia, Europe and the US. To date, the company has raised $35M in venture funding from backers including Blackbird, Rembrandt and Salesforce Ventures.

Source: Ortto, Inc.

PR Newswire

US proteomics sector set for shake-up as new IonOpticks tech unveiled

Leave a comment

IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users

MELBOURNE, Australia, March 3, 2023 /PRNewswire/ — IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new TS product range to the US market at US HUPO’s (US Human Proteome Organization) 19th Annual Conference in Chicago on 4-8th March, a renowned event attended by proteomics experts from around the globe.

IonOpticks’ new TS range was developed as a simple plug-and-play, fully integrated heating and source solution for Thermo Scientific mass spectrometer users, who have previously only been able to access the results achievable with IonOpticks Aurora Series columns by creating their own interface – a costly and difficult alternative.

“Researchers can now easily unlock the full potential of their mass specs through the launch of our new TS range. Thermo Orbitraps have been cited in roughly 85% of all publications related to proteomics in the last decade, so we’re excited to make our famed Aurora Series products easily accessible to this significant portion of the mass spec community,” says Xavier Perronnet, Managing Director at IonOpticks.

“We’re excited to be attending US HUPO, to meet with our peers and showcase how the TS, combined with our Aurora Series columns, can provide Thermo mass spec users the ability to supercharge the sensitivity of their existing instruments. Our columns enable researchers to delve deeper into their samples than ever before.” Mr Perronnet continues.

The combination of IonOpticks’ proprietary nanoZero® fittings and integrated emitter with the new TS range removes all pre- and post-column dead volume, maximizing the capacity of the chromatographic packed bed to separate samples. Further, the heating solution in the TS is reusable which saves users both time and money while reducing unnecessary waste.

The TS range was developed following the paradigm-shifting release of the Aurora Frontier – the first ever column to routinely generate over 10,000 protein identifications on a Thermo mass spectrometer – from a single sample and single species.

“The results that have been achieved with our Aurora Frontier have been outstanding and we’re proud to continue to develop products that enable us to ensure access to these gains is equal for all researchers,” says Dr Jarrod Sandow, Head of Product Development at IonOpticks.

“Thermo users continue to be top customers of our products, so we’ve worked hard behind the scenes to ensure these users can easily boost the performance of their existing instruments through a simple all-in-one heating and source integration system. One that requires no complex installation and is ready to use straight out of the box,” Dr Sandow adds.

IonOpticks is committed to ensuring the world’s best chromatography is available to all mass spec users. Alongside the TS, IonOpticks have also launched the SX, a fully integrated column heating and interface solution for SCIEX users.

About IonOpticks

IonOpticks produces high-performance chromatography solutions for the global research community.

We specialise in the development and manufacture of columns for analytical applications in liquid chromatography with mass spectrometry (LC-MS) and high-end proteomics. Our highly reproducible methods provide a unique ability to enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples.

Our team are experts in a broad array of LC-MS platform technologies and are driven by the need to improve chromatographic performance in order to achieve data quality and deep proteome coverage on a whole new scale.

https://ionopticks.com/ / https://www.proteomicssolved.com/

Cision View original content:https://www.prnewswire.com/news-releases/us-proteomics-sector-set-for-shake-up-as-new-ionopticks-tech-unveiled-301760866.html

PR Newswire

Guardant Health to integrate Lunit’s AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection

Leave a comment

  • Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC
  • Lunit’s AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health’s portfolio of cancer tests

SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), in partnership with leading precision oncology company Guardant Health, today announced the integration of its AI-based PD-L1 scoring algorithm into Guardant’s testing workflow to enhance biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).

The newly integrated algorithm will enable Guardant to offer augmented biomarker assessment for NSCLC patients through AI-based quantification of tissue samples using a scoring system generated by Lunit SCOPE PD-L1. The enhanced Guardant test is designed to support pathologists in diagnosing PD-L1 status with higher accuracy and efficiency. Through the AI software, the test showed improved detection of PD-L1 by more than 20 percent compared to manual pathologist interpretation in the most challenging cases in NSCLC1.

Lunit SCOPE PD-L1 is a CE-marked AI solution for detecting and analyzing PD-L1, a cancer biomarker. The solution may assist pathologists by minimizing interpretation discrepancy and allowing better prediction of treatment outcomes for non-small cell lung cancer (NSCLC) patients, as demonstrated in study findings published in the European Journal of Cancer.

Lunit SCOPE PD-L1’s integration with the Guardant360 TissueNext PD-L1 test is the first application in Guardant Galaxy, Guardant Health’s suite of technology applications developed internally and through outside partnerships to enhance the performance and utility of its portfolio of cancer tests.

The two companies have been in partnership since 2021, following a strategic investment from Guardant Health to Lunit.

“We are honored to partner with Guardant Health in leveraging the power of AI and digital pathology to enhance the capabilities of their comprehensive genomic profiling tests for cancer patients,” said Brandon Suh, CEO of Lunit. “The development of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 test is a great example of using advanced medical image analytics to enhance precision diagnostics in lung cancer and help doctors find the right treatment for the right patients.”

“With Guardant Galaxy, we are now accessing the most advanced AI techniques and the latest complementary technologies from leading companies in cancer diagnostics to enhance the capabilities of our tests and provide oncologists and researchers with precise and actionable information,” said Helmy Eltoukhy, co-CEO of Guardant Health. “The digital pathology solution from Lunit has already demonstrated the power of AI to help improve detection of PD-L1 in certain cases of non-small cell lung cancer. We believe it has the potential to contribute much more broadly to advances in identifying cancer biomarkers and informing treatment decisions.”

About Lunit

With AI, Lunit aims to ‘conquer cancer,’ one of the leading causes of death worldwide. Lunit is an AI software company devoted to developing AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients. Lunit, a portmanteau of ‘learning unit,’ is a deep learning-based medical AI company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. Its technology has been recognized at international AI competitions surpassing top companies like Google, IBM, and Microsoft. As a medical AI company with a focus on clinical evidence, the company’s findings are presented in major peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences including ASCO and AACR. After receiving FDA clearance and the CE Mark, Lunit INSIGHT CXR and MMG are clinically used in approximately 1,000 hospitals and medical institutions across more than 40 countries. Lunit is headquartered in Seoul, South Korea with offices and representatives around the world.

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Lunit SCOPE PD-L1 is CE marked in Europe and has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantNFINITY® tests for advanced stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.

References

1. Sangjoon Choi et al. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response, European Journal of Cancer 2022, Volume 170, 17-26

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/guardant-health-to-integrate-lunits-ai-based-scoring-algorithm-for-pd-l1-into-its-portfolio-to-enhance-cancer-biomarker-detection-301734438.html

PR Newswire

Correction – Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers

Leave a comment

Correction Notice

Please note the following corrections to the Press Release issued Jan 17, 2023:

  • The CDL Health Scanner is a product of Health in Transportation. NuraLogix does not hold any liability for any applications distributed under the Health in Transportation name.
  • NuraLogix technology, service and products do not uncover, nor identify life-threatening health conditions. NuraLogix technology, service and products are intended to improve your awareness of general wellness and health.
  • Note that NuraLogix technology, service and products are For Investigational Use Only within the USA. NuraLogix technology, service and products are not a substitute for the clinical judgment of a health care professional. NuraLogix technology, service and products are not intended to diagnose, treat, mitigate or prevent any disease, symptom, disorder or abnormal physical state. Always consult with a health care professional or emergency services if you believe you may have a medical issue.
  • NuraLogix is not responsible for any third-party products that may integrate NuraLogix technology, service or products. NuraLogix does not make any claims about, nor have they evaluated the claims of any third-party products using NuraLogix technology, service or products.
  • NuraLogix technology, service and products do not predict the risk of, nor do they provide Obstructive Sleep Apnea (OSA) measurements in any way. NuraLogix technology, service and products do not provide customized health coaching from Medwell, nor sleep-apnea solutions by Dedicated Sleep. NuraLogix technology, service and products do not provide health education, or resources to assist with lifestyle changes.

Corrected Press Release

Please note the following corrected press release. A previous release sent on January 17 contained incorrect or outdated information.

ST. GEORGE, Utah, Jan. 26, 2023 /PRNewswire/ — Health in Transportation, a health and wellness solution provider for the transportation industry, released a revolutionary preventative health tool for drivers called CDL Health Scanner.

Accessed through a specific URL on a smartphone, CDL Health Scanner’s proprietary technology uses a smartphone camera to scan an individual’s face and analyze key vital signs. This unique, driver-centric system uses revolutionary technology from NuraLogix, called Transdermal Optical Imaging (TOI)™, in which a conventional video camera is used to extract blood flow information from the face. Risk factors for hypertension, type-2 diabetes and more are revealed to the individual user on an easy-to-interpret results page.

“It’s an exciting day for the transportation industry,” said Bob Perry, president of Health in Transportation. “For less than the cost of a couple coffee drinks, this new smartphone app will provide health information to drivers, potentially salvaging thousands of driving careers. Our partnership with NuraLogix is dedicated to bringing innovative solutions to directly impact the driver shortage and help keep America’s professional drivers on the road instead of being sidelined due to bad health.”

This new, confidential CDL Health Scanner was developed specifically to protect drivers. With the transportation industry experiencing a shortage of close to 80,000 drivers each year– along with the fact that putting a new driver behind the wheel often involves a five-figure expense for the carrier–thousands of skilled drivers are disqualified from driving each month due to poor health outcomes.

CDL Health Scanner not only alerts drivers of potentially serious health concerns, but it also provides health education focused on the driver and guides them toward resources that can assist with lifestyle changes. Often, drivers are completely unaware of some of these underlying medical conditions, and CDL Health Scanner aims to bring awareness to these important metrics. The app provides support for drivers who may be at risk by providing them with the nearest location of one of the six thousand Higi health check stations.

CDL Health Scanner can be purchased by visiting www.cdlhealthscanner.com.

About Health in Transportation
Health in Transportation (HIT) provides innovative and practical health and wellness solutions for professional drivers in trucking and mass transit. For almost forty years, their programs have helped thousands of drivers avoid medical disqualification with unique coaching mechanisms that drivers can utilize even while they are on the road. Known as ‘The Trucker Trainer’ by professional drivers nationwide, Bob Perry, president of HIT, brings a very distinctive perspective to the issue of a driver’s health and life expectancy. He comes from a family of professional drivers and has spent decades working on driver health initiatives.

About NuraLogix
NuraLogix are the Toronto-based pioneers of the world’s first contactless blood pressure and vital sign measurement solution. NuraLogix uses its patented Transdermal Optical Imaging (TOI™) technology in which a conventional video camera is used to extract facial blood flow information. This technology is the evolution of extensive peer-reviewed research and clinical studies, differentiating NuraLogix from their competitors. NuraLogix has conducted multiple clinical studies and published several research papers in notable scientific publications such as Frontiers in Psychology, Scientific Reports, and the Journal of Natural Sciences (JNS). To date the company has been issued 13 US patents with additional patents pending. Visit their website at www.nuralogix.ai.

For inquiries related to Anura™ and NuraLogix technology, service and products please contact Chris Lin, Chief Marketing Officer, ChrisLin@nuralogix.ai; For inquiries related to CDL Health Scanner and products and services provided by Health in Transportation, please contact Bob Perry, President of Health in Transportation,  bob@healthintransportation.com

PR Newswire

Waterdrop and Jemincare Collaborate on the “Digital Service Platform for CKD Patients”

Leave a comment

BEIJING, Jan. 4, 2023 /PRNewswire/ — Waterdrop and Jemincare recently reached a cooperation, according to which both sides will jointly launch the “Digital Service Platform for CKD Patients”. Featuring both online and offline service modules ranging from follow-up visits and consultation with doctors to interpretation of data reports and popularization of disease knowledge, the platform is expected to offer patients efficient, convenient, and integrated chronic disease management services, and enhance their experience even without visiting hospitals.

Jemincare is committed to delivering CKD patients with a better experience in drug use, diagnosis, and treatment by offering services outside hospitals throughout the course of the disease. Boasting a series of proven tools devised to improve patient management services, Waterdrop Patient Platform, built on a patient-centric approach, can provide patients with services in the whole disease course outside hospitals. The bilateral cooperation is of positive significance in helping CKD patients solve problems associated with diagnosis, drug use, and daily care during the long cycle of treatment.

According to Yao Hu, co-founder of Waterdrop and General Manager of Waterdrop’s Pharmaceutical Innovation Business Unit, Waterdrop Patient Platform enjoys a solid foundation in offering patient services across the whole disease course outside hospitals and has put in place a multi-dimensional operation system that provides patients with one-on-one Q&A services related to reporting interpretation, drug use, disease knowledge explanation, nutrition & lifestyle guidance, and psychological support. As of September 2022, the platform had served 3 million patients with severe diseases and set up nearly 1,600 communities that covered patients of 12 common serious diseases and rare diseases. “Centering on patient needs, Waterdrop Patient Platform will further optimize service processes to bring more comprehensive, professional, and considerate services to patients. Also, empowered by digital technologies, the platform can help pharmaceutical partners boost quality and efficiency.”

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about Waterdrop’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Waterdrop’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Cision View original content:https://www.prnewswire.com/news-releases/waterdrop-and-jemincare-collaborate-on-the-digital-service-platform-for-ckd-patients-301713005.html

Source: Waterdrop Inc.